Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 11, 2008, Pages 5094-5102

  Palii, Stela S ^a   Afzal, Aqeela ^a   Shaw, Lynn C ^a   Pan, Hao ^a   Caballero, Sergio ^a   Miller, Rehae C ^b   Jurczyk, Simona ^a   Reubi, Jean Claude ^c   Tan, Yufei ^d   Hochhaus, Guenther ^d   Edelhauser, Henry ^e   Geroski, Dayle ^e   Shapiro, Gideon ^a   Grant, Maria B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c RFE Pharma   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; GROWTH HORMONE; OCTREOTIDE; OXYGEN; RFE 007 PROTEIN; RFE 011 PROTEIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EYE DROPS; IMIDAZOLIDINE 2,4 DIONE; IMIDAZOLIDINE DERIVATIVE; IMIDAZOLIDINE-2,4-DIONE; RNA; SOMATOSTATIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CHOROID; CLINICAL EVALUATION; CLINICAL STUDY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; ENDOCRINE SYSTEM; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LASER; MOUSE; NEWBORN; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; RETINA; RETINOPATHY; SCLERA; SUBRETINAL NEOVASCULARIZATION; TUBE; ANIMAL; AUTORADIOGRAPHY; C57BL MOUSE; CELL CULTURE; CELL MOTION; DISEASE COURSE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; INJECTION; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; RABBIT; RETINA NEOVASCULARIZATION; TREATMENT OUTCOME; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AUTORADIOGRAPHY; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; IMIDAZOLIDINES; INJECTIONS; MICE; MICE, INBRED C57BL; OCTREOTIDE; OPHTHALMIC SOLUTIONS; POLYMERASE CHAIN REACTION; RABBITS; RECEPTORS, SOMATOSTATIN; RETINAL NEOVASCULARIZATION; RNA; SCLERA; TREATMENT OUTCOME; VITREOUS BODY;

EID: 56149120697     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2289     Document Type: Article

References (36)

1. Frank RN. On the pathogenesis of diabetic retinopathy: a 1990 update. Ophthalmology. 1991;98:586-593.
2. Zimmer-Galler IE, Bressler NM, Bressler SB. Treatment of choroidal neovascularization: updated information from recent macular photocoagulation study group reports. Int Ophthalmol Clin. 1995;35:37-57.
3. Poulsen JE. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes. 1953;2:7-12.
4. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab. 2000;85:3882-3891. (Pubitemid 30828605)
5. Grant MB, Guay C. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci. 1991;32:53-64.
6. Grant MB, Khaw PT, Schultz GS, Adams JL, Shimizu RW. Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-beta on corneal cell chemotaxis. Invest Ophthalmol Vis Sci. 1992;33:3292-3301.
7. Castellon R, Hamdi HK, Sacerio I, Aoki AM, Kenney MC, Ljubimov AV. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res. 2002;74:523-535. (Pubitemid 34757030)
8. Florio T, Morini M, Villa V, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003;144:1574-1584. (Pubitemid 36428500)
9. Poitout L, Roubert P, Contour-Galcera MO, et al. Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem. 2001;44:2990-3000. (Pubitemid 32879128)
10. Shaw LC, Afzal A, Lewin AS, Timmers AM, Spoerri PE, Grant MB. Decreased expression of the insulin-like growth factor 1 receptor by ribozyme cleavage. Invest Ophthalmol Vis Sci. 2003;44:4105-4113. (Pubitemid 37047988)
11. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
12. Sengupta N, Caballero S, Mames RN, Butler JM, Scott EW, Grant MB. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:4908-4913. (Pubitemid 37315308)
13. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961-964. (Pubitemid 30187528)
14. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
15. Rudnick DE, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci. 1999;40:3054-3058. (Pubitemid 29521626)
16. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001;33:300-306.
17. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504-509. (Pubitemid 30185795)
18. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res. 2001;33:295-299.
19. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf). 2002;57:425-441.
20. Sall JW, Klisovic DD, O'Dorisio MS, Katz SE. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res. 2004;79:465-476.
21. Wilson SH, Davis MI, Caballero S, Grant MB. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm IGF Res. 2001;11(suppl A):S53-S59. (Pubitemid 33732183)
22. Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:2329-2335. (Pubitemid 30451010)
23. Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 2001;85:266-272. (Pubitemid 32695750)
24. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm. 2003;18:601-609.
25. Kumar U, Grigorakis SI, Watt HL, et al. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat. 2005;92:175-186. (Pubitemid 40933583)
26. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer. 1994;56:681-688. (Pubitemid 24086771)
27. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept. 1993;48:267-278. (Pubitemid 23309826)
28. Woltering EA, Barrie R, O'Dorisio TM, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res. 1991;50:245-251.
29. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism. 1996;45:49-50. (Pubitemid 26281940)
30. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185. (Pubitemid 30187558)
31. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488. (Pubitemid 28559628)
32. Kao JC, Geroski DH, Edelhauser HF. Transscleral permeability of fluorescent-labeled antibiotics. J Ocul Pharmacol Ther. 2005;21:1-10.
33. Haskell CM, ed. Cancer Treatment. 5th ed. Philadelphia: W.B. Saunders Co;2001:62-86.
34. Habtemariam T, Yu P, Oryang D, et al. Modelling viral and CD4 cellular population dynamics in HIV: approaches to evaluate intervention strategies. Cell Mol Biol (Noisy-le-grand). 2001;47:1201-1208.
35. Kramerov AA, Saghizadeh M, Pan H, et al. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol. 2006;168:1722-1736.
36. Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB. Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res. 2007;74:131-144. (Pubitemid 350051023)